Oxford Brain Diagnostics

Oxford Brain Diagnostics operates at the intersection of medical imaging software, neurotechnology and dementia diagnostics. Its stated focus is distinct from approaches based primarily on brain-volume measurements: CDM® analyzes MRI-derived features of cortical grey-matter microstructure, aiming to quantify changes at a cellular level. The company describes the underlying approach as grounded in University of Oxford MRI and neuropathology research, with a histology model compared against post-mortem brain tissue. Its CDM Insights software received FDA clearance, and the company has also described UKCA self-certification, creating a route toward clinical use in the UK and US. A second market is pharmaceutical and biotech research, where the technology is intended to support trial stratification and monitoring. Its disclosed positioning is instead defined by the combination of MRI-based microstructural analysis, a clinical diagnostic product and a research-use offering. The company is private, based in Oxford, and falls within the medical-device and healthcare categories.

The company’s trajectory has moved from early-stage formation toward product commercialization and broader clinical evidence generation. Founded in 2019, it has a recorded undisclosed funding round dated Mar 1, 2019 and non-equity assistance dated Jun 3, 2020. A product inflection point came on Jan 16, 2025, when Oxford Brain Diagnostics announced FDA clearance for CDM Insights. In May 2025, it described a commercial launch of its patented CDM technology after FDA 510(k) clearance and UKCA self-certification. The company’s 2026 milestones point to continued evidence-building and organizational change: five new studies were announced for AAIC 2026 on Jul 13, 2026, followed by Jieun Choe’s appointment as CEO and board director on Sep 15, 2026. Together, these events suggest a shift from technology development toward adoption, research validation and commercial execution, but public information does not establish revenue, customer numbers or the scale of deployment.